Tau Therapeutics has investigated mibefradil dihydrochloride and its novel proprietary compounds in a wide spectrum of cancer indications. At present, Tau is investigating the potential clinical use of its compounds in metastatic melanoma, ovarian cancer and pancreatic cancer.